WO2008116956A3 - Péptidos con capacidad para unirse a la interleuquina 10 (il-10) - Google Patents

Péptidos con capacidad para unirse a la interleuquina 10 (il-10) Download PDF

Info

Publication number
WO2008116956A3
WO2008116956A3 PCT/ES2008/000181 ES2008000181W WO2008116956A3 WO 2008116956 A3 WO2008116956 A3 WO 2008116956A3 ES 2008000181 W ES2008000181 W ES 2008000181W WO 2008116956 A3 WO2008116956 A3 WO 2008116956A3
Authority
WO
WIPO (PCT)
Prior art keywords
interleukine
peptides
binding
capacity
expression
Prior art date
Application number
PCT/ES2008/000181
Other languages
English (en)
French (fr)
Other versions
WO2008116956A2 (es
Inventor
Careaga Lorea Manterola
Lagar Ines Noelia Casares
Farray Nancy Diaz-Valdes
De Las Herrerias Javier Dotor
Sagastibelza Juan Jose Lasarte
Ugarriza Pablo Sarobe
Valtuena Jesus Prieto
Cuesta Francisco Borras
Original Assignee
Proyecto Biomedicina Cima Sl
Careaga Lorea Manterola
Lagar Ines Noelia Casares
Farray Nancy Diaz-Valdes
De Las Herrerias Javier Dotor
Sagastibelza Juan Jose Lasarte
Ugarriza Pablo Sarobe
Valtuena Jesus Prieto
Cuesta Francisco Borras
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl, Careaga Lorea Manterola, Lagar Ines Noelia Casares, Farray Nancy Diaz-Valdes, De Las Herrerias Javier Dotor, Sagastibelza Juan Jose Lasarte, Ugarriza Pablo Sarobe, Valtuena Jesus Prieto, Cuesta Francisco Borras filed Critical Proyecto Biomedicina Cima Sl
Priority to EP08750416A priority Critical patent/EP2157098A2/en
Priority to JP2010500303A priority patent/JP2010522551A/ja
Priority to BRPI0809373-3A2A priority patent/BRPI0809373A2/pt
Priority to AU2008231660A priority patent/AU2008231660A1/en
Priority to US12/593,321 priority patent/US8148334B2/en
Priority to CN200880015179A priority patent/CN101679488A/zh
Priority to CA002682021A priority patent/CA2682021A1/en
Priority to MX2009010451A priority patent/MX2009010451A/es
Publication of WO2008116956A2 publication Critical patent/WO2008116956A2/es
Publication of WO2008116956A3 publication Critical patent/WO2008116956A3/es
Priority to US13/415,151 priority patent/US20130064790A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8291—Hormone-influenced development
    • C12N15/8295—Cytokinins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)

Abstract

Se describen péptidos que tienen la capacidad de unirse a la interleuquina 10 (IL-10) y su empleo en el tratamiento de condiciones clínicas o alteraciones patológicas asociadas con expresión de IL-10, en particular, con una expresión elevada de IL-10, por ejemplo, enfermedades infecciosas, tumores, cánceres y situaciones de daño agudo.
PCT/ES2008/000181 2007-03-27 2008-03-27 Péptidos con capacidad para unirse a la interleuquina 10 (il-10) WO2008116956A2 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP08750416A EP2157098A2 (en) 2007-03-27 2008-03-27 Peptides with capacity for binding with interleukine 10 (il - 10)
JP2010500303A JP2010522551A (ja) 2007-03-27 2008-03-27 インターロイキン−１０（ｉｌ−１０）と結合する能力を有するペプチド
BRPI0809373-3A2A BRPI0809373A2 (pt) 2007-03-27 2008-03-27 Peptídeo com capacidsade pára unir-se à interleuquina 10 (il-10), sequência de ácido nucléico, construção de gene, vetor, célula hospedeira, composição farmacêutica, produto e processo para produzi um peptídeo
AU2008231660A AU2008231660A1 (en) 2007-03-27 2008-03-27 Peptides with the capacity to bind to interleukin-10 (IL - 10)
US12/593,321 US8148334B2 (en) 2007-03-27 2008-03-27 Peptides with capacity for binding with interleukine 10 (IL-10)
CN200880015179A CN101679488A (zh) 2007-03-27 2008-03-27 能与白介素-10(il-10)结合的肽
CA002682021A CA2682021A1 (en) 2007-03-27 2008-03-27 Peptides with the capacity to bind to interleukin-10 (il-10)
MX2009010451A MX2009010451A (es) 2007-03-27 2008-03-27 Peptidos con capacidad para unirse a la interleuquina 10 (il-10).
US13/415,151 US20130064790A1 (en) 2007-03-27 2012-03-08 Peptides with the capacity to bind to interleukin-10 (il-10)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200700806A ES2304315B1 (es) 2007-03-27 2007-03-27 Peptidos con capacidad para unirse a la interleuquina 10 (il-10).
ESP200700806 2007-03-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/415,151 Division US20130064790A1 (en) 2007-03-27 2012-03-08 Peptides with the capacity to bind to interleukin-10 (il-10)

Publications (2)

Publication Number Publication Date
WO2008116956A2 WO2008116956A2 (es) 2008-10-02
WO2008116956A3 true WO2008116956A3 (es) 2008-12-18

Family

ID=39744788

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2008/000181 WO2008116956A2 (es) 2007-03-27 2008-03-27 Péptidos con capacidad para unirse a la interleuquina 10 (il-10)

Country Status (11)

Country Link
US (2) US8148334B2 (es)
EP (1) EP2157098A2 (es)
JP (1) JP2010522551A (es)
CN (1) CN101679488A (es)
AU (1) AU2008231660A1 (es)
BR (1) BRPI0809373A2 (es)
CA (1) CA2682021A1 (es)
ES (1) ES2304315B1 (es)
MX (1) MX2009010451A (es)
RU (1) RU2009139651A (es)
WO (1) WO2008116956A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014227338A (ja) * 2013-05-17 2014-12-08 キヤノン株式会社 インドシアニングリーン含有粒子およびその製造方法
CN104231054A (zh) * 2014-09-01 2014-12-24 王跃建 Il-10多肽抑制剂
US10512673B2 (en) * 2015-01-07 2019-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of peptide-based inhibitors of the stat3-IL10 pathway for treating bacterial infection and granulomatous disease
CN104922659B (zh) * 2015-07-03 2018-04-20 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
BR102019007044A2 (pt) * 2019-04-05 2021-12-28 Universidade Federal de Uberlândia Peptídeos sintéticos com afinidade ao receptor de interleucina-10, composição farmacêutica e uso dos mesmos como imunomuduladores no tratamento de doenças autoimunes, inflamatórias ou alérgicas
CN114931547B (zh) * 2022-05-16 2023-04-28 四川大学华西医院 治疗牙槽骨损伤的多肽水凝胶及其制备方法和用途
CN117362396A (zh) * 2022-06-23 2024-01-09 浙江大学 一种特异性亲和白介素-10的亲和多肽及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08151396A (ja) * 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
EP0724016A1 (fr) * 1995-01-30 1996-07-31 Bio Merieux Polypeptides mimotopes de Toxoplasma gondii et applications
WO1997035194A2 (en) * 1996-03-21 1997-09-25 President And Fellows Of Harvard College Enantiomeric screening process, and compositions therefor
JPH10237098A (ja) * 1997-02-26 1998-09-08 Immuno Japan:Kk 糖脂質糖鎖レプリカペプチド

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031727A2 (en) * 2004-09-13 2006-03-23 President And Fellows Of Harvard College Peptides for treatment of autoimmune diseases
US20100028296A1 (en) * 2005-05-02 2010-02-04 Chavez Raymond A Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08151396A (ja) * 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
EP0724016A1 (fr) * 1995-01-30 1996-07-31 Bio Merieux Polypeptides mimotopes de Toxoplasma gondii et applications
WO1997035194A2 (en) * 1996-03-21 1997-09-25 President And Fellows Of Harvard College Enantiomeric screening process, and compositions therefor
JPH10237098A (ja) * 1997-02-26 1998-09-08 Immuno Japan:Kk 糖脂質糖鎖レプリカペプチド

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHOUAIB S ET AL: "The host-tumor immune conflict: from immunosuppression to resistance and destruction", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 18, no. 10, 1 October 1997 (1997-10-01), pages 493 - 497, XP004091987, ISSN: 0167-5699 *
DATABASE UniProt 11 June 1990 (1990-06-11), TEIJIN: "Human Leukocyte antigen DQ4 binding peptide", XP002496989, Database accession no. AAW49167 *
DATABASE UniProt 11 June 1996 (1996-06-11), "Human leukocyte antigen DQ4 binding prtoein #52", XP002496990, Database accession no. AAW49161 *
DATABASE UniProt 15 April 1997 (1997-04-15), JOLIVET-REYNAUD C: "Synthetic library peptide #6 which binds anti-T.gondii P30 antibody", XP002496991, Database accession no. AAW12281 *
DATABASE UniProt 26 November 1998 (1998-11-26), IMMUNO JAPAN INC: "Glycolipid sugar chain replica peptide #LCO12", XP002496992, Database accession no. AAW71348 *
DATABASE UniProt 5 June 1998 (1998-06-05), TEIJIN LTD.: "Human leukocyte antigen DQ4 binding peptide # 81", XP002496993, Database accession no. AAW49190 *
See also references of EP2157098A2 *
VICARI A P ET AL: "Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, JP, vol. 196, no. 4, 19 August 2002 (2002-08-19), pages 541 - 549, XP002248081, ISSN: 0022-1007 *

Also Published As

Publication number Publication date
ES2304315B1 (es) 2009-07-28
ES2304315A1 (es) 2008-10-01
MX2009010451A (es) 2009-12-14
CA2682021A1 (en) 2008-10-02
JP2010522551A (ja) 2010-07-08
AU2008231660A1 (en) 2008-10-02
WO2008116956A2 (es) 2008-10-02
US20130064790A1 (en) 2013-03-14
EP2157098A2 (en) 2010-02-24
BRPI0809373A2 (pt) 2014-11-11
US20100168015A1 (en) 2010-07-01
US8148334B2 (en) 2012-04-03
RU2009139651A (ru) 2011-05-10
CN101679488A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
WO2008116956A3 (es) Péptidos con capacidad para unirse a la interleuquina 10 (il-10)
ZA200711117B (en) Isolated cells and populations comprising same for the treatment of cns diseases
WO2006124880A3 (en) Systems and methods to facilitate endoscopic interventions
WO2006015035A8 (en) Useful compounds for hpv infection
UA105210C2 (ru) Противораковая вакцина и ее применение
HK1124548A1 (en) Human anti-il-23 antibodies, compositions, methods and uses il-23
WO2004067023A3 (en) Survivin-derived peptides and use thereof
WO2009052439A3 (en) Immunotherapy regimes dependent on apoe status
WO2008045021A3 (en) Blood compatible nanomaterials and methods of making and using the same
EP1784639A4 (en) PROCESS FOR PREPARING FREEZERTED BLOOD PLATES, FLUIDIZED BLOOD PLATES, COMPOSITIONS AND USE METHOD
WO2008054676A3 (en) Medical devices and methods of using the same
EP1713547A4 (en) Patient interface assembly supported under the mandible
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2009049184A9 (en) Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
EP1940456A4 (en) WWOX GENE, VECTORS COMPRISING THE SAME, AND USES THEREOF IN THE TREATMENT OF CANCER
EP2433959A3 (en) Identification of tumor-associated antigens for diagnosis and therapy
EP2842582A3 (en) Medical devices containing silicate and carbon particles
WO2008106646A3 (en) Methods and formulations for topical gene therapy
WO2006108670A3 (en) Use of cd25 antibodies in immunotherapy
WO2007147600A3 (en) Differential il-4 and/or il-10 cytokine expression in human cancer
WO2007027344A3 (en) Compounds and methods for the treatment of cancer
HK1116186A1 (en) Azaxanthones and use thereof for treating tumors
WO2008112903A3 (en) Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880015179.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08750416

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2682021

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/010451

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2010500303

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12593321

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3655/KOLNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008231660

Country of ref document: AU

Ref document number: 2008750416

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009139651

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2008231660

Country of ref document: AU

Date of ref document: 20080327

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0809373

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090928